Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma

In a phase 1b–2 study, a five-agent treatment aimed at tumor survival pathways in relapsed and refractory diffuse large B-cell lymphoma was associated with a complete response in 38% of the patients.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2024-06, Vol.390 (23), p.2143-2155
Hauptverfasser:	Melani, Christopher, Lakhotia, Rahul, Pittaluga, Stefania, Phelan, James D., Huang, Da Wei, Wright, George, Simard, Jillian, Muppidi, Jagan, Thomas, Craig J., Ceribelli, Michele, Tosto, Frances A., Yang, Yandan, Xu, Weihong, Davies-Hill, Theresa, Pack, Svetlana D., Peer, Cody J., Arisa, Oluwatobi, Mena, Esther, Lindenberg, Liza, Bergvall, Ethan, Portell, Craig A., Farah, Rafic J., Lee, Seung Tae, Pradhan, Amynah, Morrison, Candis, Tadese, Atekelt, Juanitez, Anna Marie, Lu, Crystal, Jacob, Allison, Simmons, Heidi, Figg, William D., Steinberg, Seth M., Jaffe, Elaine S., Roschewski, Mark, Staudt, Louis M., Wilson, Wyndham H.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenine - administration & dosage Adenine - adverse effects Adenine - analogs & derivatives Adenine - therapeutic use Adult Aged Aged, 80 and over Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bcl-2 protein Bcl-6 protein Biopsy Bridged Bicyclo Compounds, Heterocyclic - administration & dosage Bridged Bicyclo Compounds, Heterocyclic - adverse effects Bridged Bicyclo Compounds, Heterocyclic - therapeutic use Disease prevention Drug development Drug dosages Female Hematology Hemorrhage Humans Kinases Lenalidomide - administration & dosage Lenalidomide - adverse effects Lenalidomide - therapeutic use Leukemia Lymphocytes B Lymphoma Lymphoma, Large B-Cell, Diffuse - drug therapy Lymphoma, Large B-Cell, Diffuse - mortality Male Medical prognosis Middle Aged Molecular Targeted Therapy Myc protein Neutropenia Oncology Piperidines - administration & dosage Piperidines - adverse effects Piperidines - therapeutic use Prednisone Prednisone - administration & dosage Prednisone - adverse effects Prednisone - therapeutic use Progression-Free Survival Pyrazoles - administration & dosage Pyrazoles - adverse effects Pyrazoles - therapeutic use Pyrimidines - administration & dosage Pyrimidines - adverse effects Pyrimidines - therapeutic use Recurrence Sulfonamides - administration & dosage Sulfonamides - adverse effects Sulfonamides - therapeutic use Thrombocytopenia Tomography Treatments in Oncology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In a phase 1b–2 study, a five-agent treatment aimed at tumor survival pathways in relapsed and refractory diffuse large B-cell lymphoma was associated with a complete response in 38% of the patients.
ISSN:	0028-4793 1533-4406 1533-4406
DOI:	10.1056/NEJMoa2401532